[1]
|
Ascherio, A. and Schwarzschild, M.A. (2016) The Epidemiology of Parkinson’s Disease: Risk Factors and Revention. The Lancet Neurology, 15, 1257-1272. https://doi.org/10.1016/S1474-4422(16)30230-7
|
[2]
|
Berrios, G.E. (2016) Introdução à “Paralisia agitante”, de James Parkinson (1817). Revista Latinoamericana de Psicopatologia Fundamental, 19, 114-121. https://doi.org/10.1590/1415-4714.2016v19n1p114.9
|
[3]
|
Postuma, R.B., Berg, D., Stern, M., Poewe, W., Olanow, W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A.E., Halliday, G., Goetz, C.G., Gasser, T., Dubois, B., Chan, P., Bloem, B.R., Adler, C.H. and Deuschi, G. (2015) MDS Clinical Diagnostic Criteria for Parkinson’s Disease. Movement Disorders, 39, 1591-1599. https://doi.org/10.1002/mds.26424
|
[4]
|
Lotharius, J. and Brundin, P. (2002) Pathogenesis of Parkinson’s Disease: Dopamine, Vesicles and Alpha-Synuclein. Nature Reviews Neuroscience, 3, 932-942. https://doi.org/10.1038/nrn983
|
[5]
|
Steidl, E.M.S., Ziegler, J.R. and Ferreira, F.V. (2007) Doença de Parkinson: Revisão Bibliográfica. Disciplinarum Scientia, 8, 115-129.
|
[6]
|
Cheng, H.C., Ulane, C.M. and Bruke, R.E. (2010) Clinical Progression in Parkinson’s Disease and the Neurobiology of Axons. Annals of Neurology, 67, 715-725. https://doi.org/10.1002/ana.21995
|
[7]
|
Schapira, A.H.V., Chaudhuri, K.R. and Jenner, P. (2017) Non-Motor Features of Parkinson Disease. Nature Reviews Neuroscience, 18, 435-450. https://doi.org/10.1038/nrn.2017.62
|
[8]
|
Pagonabarraga, J., Kulisevsky, J., Strafella, A.P. and Krack, P. (2015) Apathy in Parkinson’s Disease: Clinical Features, Neural Substrates, Diagnosis, and Treatment. The Lancet Neurology, 14, 528-531. https://doi.org/10.1016/S1474-4422(15)00019-8
|
[9]
|
Pont-Sunyer, C., Hotter, A., Gaig, C., Seppi, K., Compta, Y., Katzenschlager, R., Mas, N., Hofeneder, D., Brücke, T., Bayés, A., Enzel, K., Infante, J., Zach, H., Pirker, W., Posada, I.J., álvarez, R., Ispierto, L., De Fàbregues, O., Callén, A., Palasó, A., Aguilar, M., Martí, M.J., Vallderiola, F., Salamero, M., Poewe, W. and Tolosa, E. (2014) The Onset of Nonmotor Symptoms in Parkinson’s Disease (The ONSET PD Study). Movement Disorders, 30, 229-237. https://doi.org/10.1002/mds.26077
|
[10]
|
Martinez-Martin, P., Chaudhuri, K.R., Rojo-Abuin, J.M., Rodriguez-Blazquez, C., Alvarez-Sanchez, M., Arakaki, T., Bergareche-Yarza, A., Chade, A., Garreto, N., Gershanik, O., Kurtis, M.M., Martinez-Castrillo, J.C., Mendoza-Rodriguez, A., Moore, H.P., Rodriguez-Violante, M., Singer, C., Tilley, B.C., Huang, J., Stebbins, G.T. and Goetz, C.G. (2013) Assessing the Non-Motor Symptoms of Parkinson’s Disease: MDS-UPDRS and NMS Scale. European Journal of Neurology, 22, 37-43. https://doi.org/10.1111/ene.12165
|
[11]
|
Draoui, A., El Hiba, O., Aimrane, A., El Khiat, A. and Gamrani, H. (2020) Parkinson’s Disease: From Bench to Bedside. Revue Neurologique, 176, 543-559. https://doi.org/10.1016/j.neurol.2019.11.002
|
[12]
|
Cumming, J.L. (1992) Depression and Parkinson’s Disease: A Review. The American Journal of Psychiatry, 149, 443-454. https://doi.org/10.1176/ajp.149.4.443
|
[13]
|
Reijnders, J.S.A.M., Ehrt, U., Weber, W.E.J., Aarsland, D. and Leentjens, A.F.G. (2008) A Systematic Review of Prevalence Studies of Depression in Parkinson’s Disease. Movement Disorders, 23, 183-189. https://doi.org/10.1002/mds.21803
|
[14]
|
Riedel, O., Heuser, I., Klotsche, J., Dodel, R. and Wittchen, H.U. (2010) Occurrence Risk and Structure of Depression in Parkinson Disease with and without Dementia: Results from GEPAD Study. Journal of Geriatric Psychiatry and Neurology, 23, 27-34. https://doi.org/10.1177/0891988709351833
|
[15]
|
Nilsson, F.M., Kessing, L.V. Sørensen, T.M., Andersen, P.K. and Bolwig, T.G. (2002) Major Depressive Disorder in Parkinson’s Disease: A Register-Based Study. Acta Psychiatrica Scandinavica, 106, 202-211. https://doi.org/10.1034/j.1600-0447.2002.02229.x
|
[16]
|
Julien, C.L., Rimes, K.A. and Brown, R.G. (2016) Rumination and Behavioural Factors in Parkinson’s Disease Depression. Journal of Psychosomatic Research, 82, 48-52. https://doi.org/10.1016/j.jpsychores.2016.01.008
|
[17]
|
Grover, S., Somaiya, N., Kumar, S. and Avasthi, A. (2015) Psychiatric Aspects of Parkinson’s Disease. Journal of Neurosciences in Rural Practice, 6, 65-76. https://doi.org/10.4103/0976-3147.143197
|
[18]
|
Santos, J.R., Cunha, J.A.S., Dierschnabel, A.L., Campêlo, C.L.C., Leão, A.H.F.F., Silva, A.F., Engelberth, R.C.G.J., Izídio, G.S., Cavalcante, J.S., Abílio, V.C., Ribeiro, A.M. and Silva, R.H. (2013) Cognitive, Motor and Tyrosine Hydroxylase Temporal Impairment in a Model of Parkinsionism Induced by Reserpine. Behavioural Brain Research, 253, 68-77. https://doi.org/10.1016/j.bbr.2013.06.031
|
[19]
|
Leão, A.H., Sarmento-Silva, A.J. and Santos, J.R. (2015) Molecular, Neurochemical, and Behavioral Hallmarkers of Reserpine as a Model for Parkinson’s Disease: New Perspectives to a Long-Standing Model. Brain Pathology, 25, 377-390. https://doi.org/10.1111/bpa.12253
|
[20]
|
Leão, A.H.F.F., Meurer, Y.S.R., da Silva, A.F., Medeiros, A.M., Campêlo, C.L.C., Abílio, V.C., Engelberth, R.C.G.K., Cavalvante, J.S., Izídio, G.S., Ribeiro, A.M. and Silva, R.H. (2017) Spontaneously Hypertensive Rats (SHR) Are Resistant to a Reserpine-Induced Progressive Model of Parkinson’s Disease: Differences in Motor Behavior, Tyrosine Hydroxylase and α-Synuclein Expression. Frontiers in Aging Neuroscience, 9, Article No. 78.
|
[21]
|
Fernandes, V.S., Santos, J.R., Leão, A.H., Medeiros, A.M., Melo, T.G., Izídio, G.S., Cabral, A., Ribeiro, R.A., Abílio, V.C., Ribeiro, A.M. and Silva, R.H. (2012) Repeated Treatment with a Low Dose of Reserpine as a Progressive Model of Parkinson’s Disease. Behavior Brain Research, 231, 154-163. https://doi.org/10.1016/j.bbr.2012.03.008
|
[22]
|
Campêlo, C.L.C., Santos, J.R., Silva, A.F., Dierschnabel, A.L., Pontes, A., Cavalcante, J.S., Ribeiro, A.M. and Silva, R.H. (2017) Exposure to an Enriched Environment Facilitates Motor Recovery and Prevents Short-Term Memory Impairment and Reduction of Stiatal BDNF in a Progressive Pharmacological Model of Parkinsonism in Mice. Behavior Brain Research, 328, 138-148. https://doi.org/10.1016/j.bbr.2017.04.028
|
[23]
|
Grandi, L.C., Di Giovanni, G. and Galati, A. (2018) Animal Models of Early-Stage Parkinson’s Disease and Acute Dopamine Deficiency to Study Compensatory Neurodegenerative Mechanisms. Journal of Neuroscience Methods, 308, 205-218. https://doi.org/10.1016/j.jneumeth.2018.08.012
|
[24]
|
Deumens, R., Blokland, A. and Prickaerts, J. (2002) Modeling Parkinson’s Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway. Experimental Neurology, 175, 303-317.
|
[25]
|
Schober, A. (2004) Classic Toxin-Induced Animal Models of Parkinson’s Disease: 6-OHDA and MPTP. Cell Tissue Res, 318, 215-224.
|
[26]
|
Jiang, P.E., Lang, Q.H., Yu, Q.Y., Tang, X.Y., Liu, Q.Q., Li, X.Y. and Feng, X.Z. (2019) Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-Induced Parkinson’s Disease Model. Journal of Visualized Experiments, 7. https://doi.org/10.3791/58653
|
[27]
|
Han, Q.W., Yuan, Y.H. and Chen N.H. (2019) The Therapeutic Role of Cannabinoid Receptors and Its Agonists or Antagonists in Parkinson’s Disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 96, Article ID: 109745. https://doi.org/10.1016/j.pnpbp.2019.109745
|
[28]
|
Kaji, Y. and Hirata, K. (2011) Apathy and Anhedonia in Parkinson’s Disease. International Scholarly Research Notices, 2011, Article ID: 219427. https://doi.org/10.5402/2011/219427
|
[29]
|
Remy, P., Doder, M., Lees, A., Turjanski, N. and Brooks, D. (2005) Depression in Parkinson’s Disease: Loss of Dopamine and Noradrenaline Innervation in the Limbic System. Brain, 128, 1324-1322. https://doi.org/10.1093/brain/awh445
|
[30]
|
Cléry-Melin, M., Jollant F. and Gorwood, P. (2018) Reward Systems and Cognitions in Major Depressive Disorder. CNS Spectrums, 24, 64-77. https://doi.org/10.1017/S1092852918001335
|
[31]
|
Dean, J. and Keshavan, M. (2017) The Neurobiology of Depression: An Integrated View. Asian Journal of Psychiatry, 27, 101-111. https://doi.org/10.1016/j.ajp.2017.01.025
|
[32]
|
Belujon, P. and Grace, A.A. (2017) Dopamine System Dysregulation in Major Depressive Disorders. International Journal of Neuropsychopharmacology, 20, 1036-1046. https://doi.org/10.1093/ijnp/pyx056
|
[33]
|
Kaminska, K., Lenda, T., Konieczny, J., Czarnecka, A. and Lorenc-Koci, E. (2017) Depressive-Like Neurochemical and Behavioral Markers of Parkinson’s Disease after 6-OHDA Administered Unilaterally to the Rat Medial Forebrain Bundle. Pharmacological Reports, 69, 985-994. https://doi.org/10.1016/j.pharep.2017.05.016
|
[34]
|
Skalisz, L.L., Beijamini, V., Joca, S.L., Vital, M.A.B.F., Da Cunha, C. and Andreatini, R. (2002) Evaluation of the Face Validity of Reserpine Administration as an Animal Model of Depression-Parkinson’s Disease Association. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26, 879-883. https://doi.org/10.1016/S0278-5846(01)00333-5
|
[35]
|
Mashour, N.H., Lin, G.I. and Frishman, W.H (1998) Herbal Medicine for the Treatment of Cardiovascular Disease: Clinical Considerations. Archives of Internal Medicine, 158, 2225-2234. https://doi.org/10.1001/archinte.158.20.2225
|
[36]
|
Rejintes, M. and Meyer, P.T. (2019) No Free Lunch with Herbal Preparations: Lessons from a Case of Parkinsonism and Depression Due to Herbal Medicine Containing Reserpine. Frontiers in Neurology, 23, 183-189. https://doi.org/10.3389/fneur.2019.00634
|
[37]
|
Zhu, G.H., Sun, X.P., Li, J., Pi, L., Tang, H.Q., Gao, H.Q., Cong, H.L., Qu, P., Lu, X.Z., Zhang, X.J., Zhao, L.S., Gui, Y.F., Liu, D.X., Zhang, L.Q., Tang, H., Hu, Y.X., Fan, L. and Hua, Q. (2019) No Association between Low-Dose Reserpine Use and Depression in Older Hypertensive Patient: Result of a Multicenter, Cross-Sectional Study. Journal of Geriatric Cardiology, 16, 608-613.
|
[38]
|
Baumeister, A.A., Hawkins, M.F. and Uzelac, S.M. (2003) The Myth of Reserpine-Induced Depression: Role in the Historical Development of the Monoamine Hypothesis. Journal of the History of the Neurosciences, 12, 207-220. https://doi.org/10.1076/jhin.12.2.207.15535
|
[39]
|
Lemieux, G., Davignon, A. and Genest, J. (1956) Depressive States during Rauwolfia Therapy for Arterial Hypertension: A Report of 30 Cases. Canadian Medical Association Journal, 74, 522-526.
|